Table 3.

Summary of studies that have investigated breast cancer patients with somatic BRCA mutated (sBRCA) tumors who were treated with PARP inhibitors.

Clinical Trial	Phase	Treatment	sBRCA	gBRCA	Results
Olaparib expanded [70]	2	Olaparib	n = 16	n = 0	ORR for sBRCA1/2 carriers was 50%. Median PFS for sBRCA1/2 carriers was 6.2 months.
COMETAbreast study [68]	2	Olaparib	n = 11	n = 0	Heavily pre-treated patients, no clinically or statistically significant antitumor activity. Median PFS: 2 months (95% CI: 1–4) Median OS: 9 months (95% CI: 1–14)
LUCY study [69]	3b	Olaparib	n = 3	n = 253	Small patient number for sBRCA, limited assessment of the clinical effectiveness.
Walsh et al. [71]	rObs	Olaparib	n = 4	+	Median PFS: -sBRCA1/2: 6.5 months (range 5–9) -non-BRCA1/2/HRR: 3 months (range 2–4)
RUBY trial [73]	2	rucaparib	n = 4	+	sBRCA1: 1 SD sBRCA2: 1 PR

gBRCA: germline BRCA mutation; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; PR: partial response; rObs: a single institution, retrospective observational study; SD: stable disease.